OncoSec Medical Inc (ONCS) Forecasted to Post Q3 2019 Earnings of ($0.14) Per Share

Share on StockTwits

OncoSec Medical Inc (NASDAQ:ONCS) – Analysts at Piper Jaffray Companies lifted their Q3 2019 earnings per share (EPS) estimates for shares of OncoSec Medical in a report issued on Monday, March 11th. Piper Jaffray Companies analyst E. Tenthoff now anticipates that the biotechnology company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.18). Piper Jaffray Companies also issued estimates for OncoSec Medical’s Q4 2019 earnings at ($0.15) EPS, FY2019 earnings at ($0.56) EPS, Q1 2020 earnings at ($0.14) EPS, Q2 2020 earnings at ($0.16) EPS, Q3 2020 earnings at ($0.17) EPS, Q4 2020 earnings at ($0.18) EPS and FY2020 earnings at ($0.65) EPS.

Separately, Maxim Group set a $5.00 target price on OncoSec Medical and gave the company a “buy” rating in a research report on Thursday, November 29th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. OncoSec Medical presently has an average rating of “Hold” and a consensus price target of $4.00.

Shares of OncoSec Medical stock opened at $0.56 on Thursday. OncoSec Medical has a 52 week low of $0.42 and a 52 week high of $2.21.

OncoSec Medical (NASDAQ:ONCS) last released its earnings results on Friday, December 14th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONCS. Geode Capital Management LLC raised its position in OncoSec Medical by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 163,405 shares during the last quarter. Northern Trust Corp grew its stake in shares of OncoSec Medical by 33.6% in the 4th quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after buying an additional 28,914 shares during the last quarter. Moloney Securities Asset Management LLC grew its stake in shares of OncoSec Medical by 117.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after buying an additional 27,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in OncoSec Medical by 484.1% during the 4th quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 83,150 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in OncoSec Medical by 98.2% during the 4th quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after purchasing an additional 240,843 shares during the last quarter. 6.41% of the stock is owned by institutional investors.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Featured Story: Benefits of owning preferred stock

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

WEC Energy Group Inc  Position Cut by Dean Investment Associates LLC
WEC Energy Group Inc Position Cut by Dean Investment Associates LLC
Cambria Investment Management L.P. Acquires 3,550 Shares of SPDR S TR/CITI INTL GOVT INFL
Cambria Investment Management L.P. Acquires 3,550 Shares of SPDR S TR/CITI INTL GOVT INFL
Cedar Brook Financial Partners LLC Buys 140 Shares of ProShares Ultra S&P500
Cedar Brook Financial Partners LLC Buys 140 Shares of ProShares Ultra S&P500
Cooper Companies Inc  Shares Bought by Commerce Bank
Cooper Companies Inc Shares Bought by Commerce Bank
Cambridge Investment Research Advisors Inc. Acquires 9,232 Shares of VANGUARD SCOTTS/VANGUARD SHORT-TERM
Cambridge Investment Research Advisors Inc. Acquires 9,232 Shares of VANGUARD SCOTTS/VANGUARD SHORT-TERM
SALT   Trading 18.2% Lower  Over Last Week
SALT Trading 18.2% Lower Over Last Week


© 2006-2019 Ticker Report